NASDAQ, TSX: NVCN
VANCOUVER, June 13, 2017 /PRNewswire/- Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to
announce the results of the votes on matters considered at its
Annual General Meeting of Shareholders held on June 13, 2017 in Vancouver, B.C. (the "Meeting").
At the Meeting, the shareholders of the Company (the
"Shareholders") re-elected board members Alexei Marko, Paul
Geyer, Dr. Jane Hsiao,
Steven Rubin, Dr. William O'Neill, and Doug Janzen to serve in office until the next
annual meeting or until their successors are duly elected or
appointed. Detailed results of the voting in respect of the
election of directors are as follows:
|
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
|
Alexei
Marko
|
32,285,445
|
99.68%
|
103,617
|
0.32%
|
|
Paul Geyer
|
32,293,813
|
99.71%
|
95,248
|
0.29%
|
|
Dr. Jane
Hsiao
|
31,123,483
|
96.09%
|
1,265,579
|
3.91%
|
|
Steven
Rubin
|
31,696,494
|
97.86%
|
692,568
|
2.14%
|
|
Dr. William
O'Neill
|
32,288,809
|
99.69%
|
100,252
|
0.31%
|
|
Doug
Janzen
|
32,292,535
|
99.70%
|
96,527
|
0.30%
|
At the Meeting, the Shareholders also approved amendments to the
Company's stock option plan and the unallocated options thereunder
(97.06% of votes cast in favour) and re-appointed Grant Thornton
LLP, Chartered Accountants as auditors of the Company (99.81% of
votes cast in favour).
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc
Reducer™, for the treatment of refractory angina which is not
currently available in the United
States and has been available in Europe since 2015 and the Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under investigation in the United
States, Canada and
Europe. The Company also sells a
line of advanced biological tissue products that are used as key
components in third-party medical products including transcatheter
heart valves. For more information, visit:
www.neovasc.com.
SOURCE Neovasc Inc.